These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21477408)

  • 1. Using cognitive decline in novel trial designs for primary prevention and early disease-modifying therapy trials of Alzheimer's disease.
    Darby D; Brodtmann A; Woodward M; Budge M; Maruff P
    Int Psychogeriatr; 2011 Nov; 23(9):1376-85. PubMed ID: 21477408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study.
    Burnham SC; Raghavan N; Wilson W; Baker D; Ropacki MT; Novak G; Ames D; Ellis K; Martins RN; Maruff P; Masters CL; Romano G; Rowe CC; Savage G; Macaulay SL; Narayan VA; ;
    J Alzheimers Dis; 2015; 46(4):1079-89. PubMed ID: 26402634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term observation of a multicomponent cognitive intervention in mild cognitive impairment.
    Buschert VC; Giegling I; Teipel SJ; Jolk S; Hampel H; Rujescu D; Buerger K
    J Clin Psychiatry; 2012 Dec; 73(12):e1492-8. PubMed ID: 23290333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CERAD neuropsychological compound scores are accurate in detecting prodromal alzheimer's disease: a prospective AddNeuroMed study.
    Paajanen T; Hänninen T; Tunnard C; Hallikainen M; Mecocci P; Sobow T; Tsolaki M; Vellas B; Lovestone S; Soininen H
    J Alzheimers Dis; 2014; 39(3):679-90. PubMed ID: 24246420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease.
    Zhang RY; Leon AC; Chuang-Stein C; Romano SJ
    Clin Trials; 2011 Feb; 8(1):5-14. PubMed ID: 21335586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The trajectory of cognitive decline in the pre-dementia phase in memory clinic visitors: findings from the 4C-MCI study.
    Hamel R; Köhler S; Sistermans N; Koene T; Pijnenburg Y; van der Flier W; Scheltens P; Aalten P; Verhey F; Visser PJ; Ramakers I
    Psychol Med; 2015 May; 45(7):1509-19. PubMed ID: 25407094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.
    Cummings J; Ritter A; Zhong K
    J Alzheimers Dis; 2018; 64(s1):S3-S22. PubMed ID: 29562511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of High-Frequency In-Home Monitoring Data May Reduce Sample Sizes Needed in Clinical Trials.
    Dodge HH; Zhu J; Mattek NC; Austin D; Kornfeld J; Kaye JA
    PLoS One; 2015; 10(9):e0138095. PubMed ID: 26379170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
    Vos S; van Rossum I; Burns L; Knol D; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Handels R; L'Italien G; van der Flier W; Aalten P; Teunissen C; Barkhof F; Blennow K; Wolz R; Rueckert D; Verhey F; Visser PJ
    Neurobiol Aging; 2012 Oct; 33(10):2272-81. PubMed ID: 22264648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining and labeling disease-modifying treatments for Alzheimer's disease.
    Cummings JL
    Alzheimers Dement; 2009 Sep; 5(5):406-18. PubMed ID: 19751920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.
    Yu P; Dean RA; Hall SD; Qi Y; Sethuraman G; Willis BA; Siemers ER; Martenyi F; Tauscher JT; Schwarz AJ
    J Alzheimers Dis; 2012; 32(2):373-85. PubMed ID: 22796873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
    Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
    Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient and carer views on participating in clinical trials for prodromal Alzheimer's disease and mild cognitive impairment.
    Lawrence V; Pickett J; Ballard C; Murray J
    Int J Geriatr Psychiatry; 2014 Jan; 29(1):22-31. PubMed ID: 23649902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementing a Memory Clinic Model to Facilitate Recruitment into Early Phase Clinical Trials for Mild Cognitive Impairment and Alzheimer's Disease.
    Park L; Kouhanim C; Lee S; Mendoza Z; Patrick K; Gertsik L; Aguilar C; Gullaba D; Semenova S; Jhee S
    J Prev Alzheimers Dis; 2019; 6(2):135-138. PubMed ID: 30756120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and sample size considerations for Alzheimer's disease prevention trials using multistate models.
    Brookmeyer R; Abdalla N
    Clin Trials; 2019 Apr; 16(2):111-119. PubMed ID: 30922116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compensatory mechanisms in higher-educated subjects with Alzheimer's disease: a study of 20 years of cognitive decline.
    Amieva H; Mokri H; Le Goff M; Meillon C; Jacqmin-Gadda H; Foubert-Samier A; Orgogozo JM; Stern Y; Dartigues JF
    Brain; 2014 Apr; 137(Pt 4):1167-75. PubMed ID: 24578544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
    Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing clinical trials to test disease-modifying agents: application to the treatment trials of Alzheimer's disease.
    Xiong C; van Belle G; Miller JP; Morris JC
    Clin Trials; 2011 Feb; 8(1):15-26. PubMed ID: 21335587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria.
    Wimo A; Ballard C; Brayne C; Gauthier S; Handels R; Jones RW; Jonsson L; Khachaturian AS; Kramberger M
    J Intern Med; 2014 Mar; 275(3):304-16. PubMed ID: 24605810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot.
    Hampel H; Lista S; Khachaturian ZS
    Alzheimers Dement; 2012 Jul; 8(4):312-36. PubMed ID: 22748938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.